4.7 Article

Multimarker Prediction of Coronary Heart Disease Risk The Women's Health Initiative

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 55, 期 19, 页码 2080-2091

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.12.047

关键词

coronary heart disease; prediction; biomarker

资金

  1. National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221]
  2. Rose Stamler Fund for Young Investigators at Northwestern University
  3. Abbott Laboratories
  4. Aegerion Pharmaceuticals
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Daiichi Sankyo
  8. GlaxoSmithKline
  9. Hoffmann-La Roche
  10. Merck
  11. Merck/Schering-Plough

向作者/读者索取更多资源

Objectives The aim of this study was to investigate whether multiple biomarkers contribute to improved coronary heart disease (CHD) risk prediction in post-menopausal women compared with assessment using traditional risk factors (TRFs) only. Background The utility of newer biomarkers remains uncertain when added to predictive models using only TRFs for CHD risk assessment. Methods The Women's Health Initiative Hormone Trials enrolled 27,347 post-menopausal women ages 50 to 79 years. Associations of TRFs and 18 biomarkers were assessed in a nested case-control study including 321 patients with CHD and 743 controls. Four prediction equations for 5-year CHD risk were compared: 2 Framingham risk score covariate models; a TRF model including statin treatment, hormone treatment, and cardiovascular disease history as well as the Framingham risk score covariates; and an additional biomarker model that additionally included the 5 significantly associated markers of the 18 tested (interleukin-6, D-dimer, coagulation factor VIII, von Willebrand factor, and homocysteine). Results The TRF model showed an improved C-statistic (0.729 vs. 0.699, p = 0.001) and net reclassification improvement (6.42%) compared with the Framingham risk score model. The additional biomarker model showed additional improvement in the C-statistic (0.751 vs. 0.729, p = 0.001) and net reclassification improvement (6.45%) compared with the TRF model. Predicted CHD risks on a continuous scale showed high agreement between the TRF and additional biomarker models (Spearman's coefficient = 0.918). Among the 18 biomarkers measured, C-reactive protein level did not significantly improve CHD prediction either alone or in combination with other biomarkers. Conclusions Moderate improvement in CHD risk prediction was found when an 18-biomarker panel was added to predictive models using TRFs in post-menopausal women. (J Am Coll Cardiol 2010;55:2080-91) (C) 2010 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据